المستجدات التنظيمية
تغييرات من الجهات التنظيمية الهندية وجهات بلدان الوجهة تؤثر في طريقة تصدير الأدوية وتوثيقها ودفع ثمنها واستيرادها، مع مصدر كل منها وما تعنيه للمشترين.
المستجدات: 10
إجابة مختصرة
يسجّل كل مستجد تغييراً واحداً مؤرّخاً، مثل إشعار جمركي أو قاعدة دفع أو إجراء استيراد جديد، مع المصدر الأساسي، ومن يتأثر به، وما ينبغي للمشترين فعله الآن. وتُوسَم المسودات بأنها مسودات إلى أن تصبح قانوناً.
أكتوبر 2026
- 25 أكتوبر 2026مسارات الوصول
Saudi SFDA updates its SAP guideline for unregistered medicines
The Saudi Food and Drug Authority has published version 2.0 of its Special Access Program guideline, dated 25 October 2026. It adds a route for rare disease medicines, splits approval from the import licence request, and sets a 7 working day decision target. The medicine must be approved by one of seven reference regulators or under registration with SFDA.
اقرأ المستجد - 12 أكتوبر 2026قواعد التصدير الهندية
CDSCO says approved r-DNA products need no separate export NOC for an export brand
A CDSCO notice of October 2026 clarifies that an r-DNA drug already holding an Indian marketing authorisation in Form CT-23 needs no separate CDSCO export NOC when the only change is a brand name used for export. Any other change keeps the quantity-specific export NOC, which matters for buyers of Indian recombinant biologics.
اقرأ المستجد
أكتوبر 2026
- 1 أكتوبر 2026المدفوعات والتسعيرالمستندات
India's FEMA 2026 export rules take effect with a nine-month realisation period
India's new Foreign Exchange Management (Export and Import of Goods and Services) Regulations 2026 took effect on 1 October 2026. An RBI amendment of 22 September 2026 cut the period for Indian exporters to receive payment from 15 months to 9 months after shipment, or 12 months for rupee invoices, which shapes payment terms offered to overseas buyers.
اقرأ المستجد - 1 أكتوبر 2026قواعد التصدير الهنديةالمستندات
Nhava Sheva extends post facto export NOC relaxation to 31 December 2026
Jawaharlal Nehru Custom House has extended to 31 December 2026 the interim relaxation that lets unapproved, new or banned drugs made for export clear with a CDSCO NOC obtained after manufacture. From 1 January 2027 these exports must fully follow the CDSCO Office Order of 30 April 2024, which affects lead times for products not approved in India.
اقرأ المستجد - 28 سبتمبر 2026قواعد التصدير الهندية
India's draft Rule 65(22) would curb prescription drug advertising by drug sellers
A draft amendment to India's Drugs Rules, G.S.R. 861(E) of 28 September 2026, would bar retail and wholesale drug licence holders, including online pharmacies and distributors, from advertising Schedule H, H1 or X medicines without prior Central Government sanction. It is a draft open for comment, not yet law, and would shape how Indian suppliers present prescription medicines online.
اقرأ المستجد
أبريل 2026
- 28 أبريل 2026التجارب السريرية
New UK clinical trials regulations take effect on 28 April 2026
The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 came into force in the UK on 28 April 2026. They speed up combined MHRA and ethics review, add a notification route for lower-risk trials and make trial registration and results publication legal duties. Sponsors and CROs sourcing comparators from India should expect shorter start-up windows.
اقرأ المستجد - 12 أبريل 2026الجودة والسلامةالشحن وسلسلة التبريد
Qatar requires two thirds of shelf life left on imported medicines
Qatar's Ministry of Public Health issued a circular, reported on 12 April 2026, requiring imported medicines to arrive with at least two thirds of their shelf life remaining. It took immediate effect for licensed agents and importers. Products that fall short need an exemption from the Department of Pharmacy and Drug Control, which matters for short-dated specialty and orphan batches.
اقرأ المستجد
ديسمبر 2025
يوليو 2025
يوليو 2025
تخطط لطلب في ظل تغيّر إحدى القواعد؟
أرسل اسم الدواء والوجهة. ويعكس عرض السعر المستندات والمدد الزمنية الحالية.